ArticlePharmaceutical research2015
The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
Article in Pharmaceutical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.Acta pharmaceutica Sinica. B · 2026Review
- Oral Treatment of Obesity by GLP-1 and Its Analogs.Pharmaceutics · 2025Review
- Enhanced lymphatic transportation of SLN by mimicking oligopeptide transportation route.Asian journal of pharmaceutical sciences · 2025Article
- Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer.Amino acids · 2021Article
- Trends of nanotechnology in type 2 diabetes mellitus treatment.Asian journal of pharmaceutical sciences · 2021Review
- Nanomedicine strategies to target coronavirus.Nano today · 2020Review
- Peptides as drug delivery vehicles across biological barriers.Journal of pharmaceutical investigation · 2018Article
- Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape.International journal of nanomedicine · 2018Review
- Microvascular NADPH oxidase in health and disease.Free radical biology & medicine · 2017Review
- Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeExenatide, a potent insulinotropic agent, can be used for the treatment of non-insulin-dependent diabetes mellitus. However, the need for frequent injections seriously limits its therapeutic utility. The aim of present report was to develop an orally available exenatide formulation using goblet cell-targeting nanoparticles (NPs).
methodThe exenatide-loaded nanoparticles were prepared with modified chitosan which was conjugated with a goblet cell-target peptide, CSKSSDYQC (CSK) peptide.
resultsThe CSK-chitosan nanoparticles shown reduced chitosan toxicity and enhanced the permeation of drugs across the Caco-2/HT-29 co-cultured cell monolayer, which simulated the intestinal epithelium. Following the oral administration of near-infrared fluorescent probe Cy-7-loaded NPs to mice, the distribution of the drugs was investigated with a near-infrared in vivo image system (FX Pro, Bruker, USA). The results showed that Cy-7 fluorescence disseminated from the oesophagus, then to stomach and small intestine and then was absorbed into hepatic, finally into the bladder; over time, Cy-7 was metabolized and excreted. The bioavailability of the modified nanoparticles was found to be 1.7-fold higher compared with the unmodified ones, and the hypoglycemic effect was also better.
conclusionCSK peptide-modified chitosan nanoparticles could be a potential therapeutics for Type II diabetes patients.
Indexed as
Identifiers
25270570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.